FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial-Reference-Cited by-同舟云学术

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial

Published:2016-10 Issue:10 Volume:17 Page:1426-1434
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Stintzing Sebastian,Modest Dominik P,Rossius Lisa,Lerch Markus M,von Weikersthal Ludwig Fischer,Decker Thomas,Kiani Alexander,Vehling-Kaiser Ursula,Al-Batran Salah-Eddin,Heintges Tobias,Lerchenmüller Christian,Kahl Christoph,Seipelt Gernot,Kullmann Frank,Stauch Martina,Scheithauer Werner,Held Swantje,Giessen-Jung Clemens,Moehler Markus,Jagenburg Andreas,Kirchner Thomas,Jung Andreas,Heinemann Volker

Publisher

Elsevier BV

Subject

Oncology

Reference21 articles.

1. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial;Heinemann;Lancet Oncol,2014

2. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada;Therasse;J Natl Cancer Inst,2000

3. Cetuximab or bevacizumab in metastatic colorectal cancer?;Sclafani;Lancet Oncol,2015

4. Progression-free survival: helpful biomarker or clinically meaningless end point?;Venook;J Clin Oncol,2015

5. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab;Piessevaux;J Clin Oncol,2013

Cited by 349 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI;ESMO Open;2024-09

2. Early tumor shrinkage as a prognostic predictor in chemotherapy-naïve patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemcitabine plus nab-paclitaxel combination therapy: An exploratory analysis of JCOG1407;Pancreatology;2024-09

3. Exploring Predictive and Prognostic Biomarkers in Colorectal Cancer: A Comprehensive Review;Cancers;2024-08-08

4. Biomarker-stratified first-line treatment of right-sided metastatic colon cancer with interdisciplinary collaboration in the IVOPAK II trial;Anti-Cancer Drugs;2024-08-07

5. Prognostic Significance of EGFR, HER2, and c-Met Overexpression in Surgically Treated Patients with Adenocarcinoma of the Ampulla of Vater;Cancers;2024-08-03